SAT-575 - Relationship between HbA1c and Albuminuria in Patients with Type 2 Diabetes Mellitus

Type 2 diabetes mellitus (T2DM) and its complications remain a major healthcare concern. Albuminuria is an early indicator of chronic kidney disease (CKD) and a significant risk factor for cardiovascular disease (CVD). While glycemic control is crucial in preventing albuminuria, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are the mainstay of CKD management. Sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are glucose-lowering agents with renoprotective effects. However, the role of emerging glucose-lowering therapies in modifying albuminuria requires further investigation.
This ongoing observational study aims to explore the relationship between HbA1c and albuminuria in T2DM patients and assess the impact of glycemic control strategies on renal outcomes.
The study includes 232 T2DM patients from Diacor Hospital, Tbilisi, Georgia. HbA1c and urinary albumin-to-creatinine ratio (UACR) were measured at baseline and after six months of intensive treatment. Preliminary analysis was conducted using ANOVA and Pearson’s correlation to evaluate trends in glycemic control and albuminuria reduction. Additional data collection and extended follow-up are in progress.
Initial findings show a significant decrease in HbA1c from 8.93% to 7.33% (P < 0.00001) and UACR reduction from 79.69 mg/L to 58.75 mg/L (P=0.00068) over six months. A positive correlation was observed between HbA1c and albuminuria at baseline (R=0.1632, P=0.0128) and at six months (R=0.1951, P=0.0028). In particular, patients treated with SGLT2 inhibitors or GLP-1 receptor agonists showed larger reductions in albuminuria. It suggests potential renoprotective effects beyond glycemic lowering.
These preliminary findings suggest a strong correlation between HbA1c and albuminuria, highlighting the importance of tight glycemic control in reducing kidney damage risk in T2DM. Ongoing data collection and extended follow-up will further clarify the long-term impact of glucose-lowering therapies on CKD and CVD prevention.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*